These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 24898317)
1. Dynamic imbalance between cancer cell subpopulations induced by transforming growth factor beta (TGF-β) is associated with a DNA methylome switch. Martin M; Ancey PB; Cros MP; Durand G; Le Calvez-Kelm F; Hernandez-Vargas H; Herceg Z BMC Genomics; 2014 Jun; 15(1):435. PubMed ID: 24898317 [TBL] [Abstract][Full Text] [Related]
2. High expression of DNMT3A and DNMT3B regulatory factors of TGFB in non-neoplastic liver tissues of HCC. Hu S; Luo X; Qian J; Hou Y; Shi W Cell Mol Biol (Noisy-le-grand); 2023 Sep; 69(9):52-61. PubMed ID: 37807334 [TBL] [Abstract][Full Text] [Related]
3. CD133+ liver cancer stem cells from methionine adenosyl transferase 1A-deficient mice demonstrate resistance to transforming growth factor (TGF)-beta-induced apoptosis. Ding W; Mouzaki M; You H; Laird JC; Mato J; Lu SC; Rountree CB Hepatology; 2009 Apr; 49(4):1277-86. PubMed ID: 19115422 [TBL] [Abstract][Full Text] [Related]
4. Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells. Song Y; Pan G; Chen L; Ma S; Zeng T; Man Chan TH; Li L; Lian Q; Chow R; Cai X; Li Y; Li Y; Liu M; Li Y; Zhu Y; Wong N; Yuan YF; Pei D; Guan XY Gastroenterology; 2015 Oct; 149(4):1068-81.e5. PubMed ID: 26099525 [TBL] [Abstract][Full Text] [Related]
5. Regulatory role of miR-142-3p on the functional hepatic cancer stem cell marker CD133. Chai S; Tong M; Ng KY; Kwan PS; Chan YP; Fung TM; Lee TK; Wong N; Xie D; Yuan YF; Guan XY; Ma S Oncotarget; 2014 Jul; 5(14):5725-35. PubMed ID: 25015418 [TBL] [Abstract][Full Text] [Related]
6. CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling. Tang KH; Ma S; Lee TK; Chan YP; Kwan PS; Tong CM; Ng IO; Man K; To KF; Lai PB; Lo CM; Guan XY; Chan KW Hepatology; 2012 Mar; 55(3):807-20. PubMed ID: 21994122 [TBL] [Abstract][Full Text] [Related]
7. Reciprocal regulation by TLR4 and TGF-β in tumor-initiating stem-like cells. Chen CL; Tsukamoto H; Liu JC; Kashiwabara C; Feldman D; Sher L; Dooley S; French SW; Mishra L; Petrovic L; Jeong JH; Machida K J Clin Invest; 2013 Jul; 123(7):2832-49. PubMed ID: 23921128 [TBL] [Abstract][Full Text] [Related]
8. Elevated expression of the stem cell marker CD133 associated with Line-1 demethylation in hepatocellular carcinoma. Zhang C; Xu Y; Zhao J; Fan L; Jiang G; Li R; Ling Y; Wu M; Wei L Ann Surg Oncol; 2011 Aug; 18(8):2373-80. PubMed ID: 21331808 [TBL] [Abstract][Full Text] [Related]
9. microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb. Zhang J; Luo N; Luo Y; Peng Z; Zhang T; Li S Int J Oncol; 2012 Mar; 40(3):747-56. PubMed ID: 22025269 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of the cancer stem cells-like properties by arsenic trioxide, involved in the attenuation of endogenous transforming growth factor beta signal. Li Y; Jiang F; Liu Q; Shen J; Wang X; Li Z; Zhang J; Lu X Toxicol Sci; 2015 Jan; 143(1):156-64. PubMed ID: 25304214 [TBL] [Abstract][Full Text] [Related]
11. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Ma S; Tang KH; Chan YP; Lee TK; Kwan PS; Castilho A; Ng I; Man K; Wong N; To KF; Zheng BJ; Lai PB; Lo CM; Chan KW; Guan XY Cell Stem Cell; 2010 Dec; 7(6):694-707. PubMed ID: 21112564 [TBL] [Abstract][Full Text] [Related]
12. Transient mTOR inhibition facilitates continuous growth of liver tumors by modulating the maintenance of CD133+ cell populations. Yang Z; Zhang L; Ma A; Liu L; Li J; Gu J; Liu Y PLoS One; 2011; 6(12):e28405. PubMed ID: 22145042 [TBL] [Abstract][Full Text] [Related]
13. Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma. Kohga K; Tatsumi T; Takehara T; Tsunematsu H; Shimizu S; Yamamoto M; Sasakawa A; Miyagi T; Hayashi N J Hepatol; 2010 Jun; 52(6):872-9. PubMed ID: 20395004 [TBL] [Abstract][Full Text] [Related]
14. Hepatic transforming growth factor beta gives rise to tumor-initiating cells and promotes liver cancer development. Wu K; Ding J; Chen C; Sun W; Ning BF; Wen W; Huang L; Han T; Yang W; Wang C; Li Z; Wu MC; Feng GS; Xie WF; Wang HY Hepatology; 2012 Dec; 56(6):2255-67. PubMed ID: 22898879 [TBL] [Abstract][Full Text] [Related]
15. Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta. You H; Ding W; Rountree CB Hepatology; 2010 May; 51(5):1635-44. PubMed ID: 20196115 [TBL] [Abstract][Full Text] [Related]
16. CD133 silencing inhibits stemness properties and enhances chemoradiosensitivity in CD133-positive liver cancer stem cells. Lan X; Wu YZ; Wang Y; Wu FR; Zang CB; Tang C; Cao S; Li SL Int J Mol Med; 2013 Feb; 31(2):315-24. PubMed ID: 23233126 [TBL] [Abstract][Full Text] [Related]
17. The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling. Lin L; Amin R; Gallicano GI; Glasgow E; Jogunoori W; Jessup JM; Zasloff M; Marshall JL; Shetty K; Johnson L; Mishra L; He AR Oncogene; 2009 Feb; 28(7):961-72. PubMed ID: 19137011 [TBL] [Abstract][Full Text] [Related]
18. Discovery of VEGFR-2 inhibitors exerting significant anticancer activity against CD44+ and CD133+ cancer stem cells (CSCs): Reversal of TGF-β induced epithelial-mesenchymal transition (EMT) in hepatocellular carcinoma. Modi SJ; Kulkarni VM Eur J Med Chem; 2020 Dec; 207():112851. PubMed ID: 33002846 [TBL] [Abstract][Full Text] [Related]
19. Phenotypic subpopulations of metastatic colon cancer stem cells: genomic analysis. Botchkina IL; Rowehl RA; Rivadeneira DE; Karpeh MS; Crawford H; Dufour A; Ju J; Wang Y; Leyfman Y; Botchkina GI Cancer Genomics Proteomics; 2009; 6(1):19-29. PubMed ID: 19451087 [TBL] [Abstract][Full Text] [Related]